Clinical Trial Update: A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (Symmetry) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update for efruxifermin in adults with nonalcoholic steatohepatitis and compensated cirrhosis shows the study is active but not recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cirrhosis
• Nonalcoholic Steatohepatitis

Drugs mentioned

• efruxifermin (efruxifermin)

Snippet

Sponsor: Akero Therapeutics, Inc | Conditions: NASH - Nonalcoholic Steatohepatitis | Phase 2 | Status: ACTIVE_NOT_RECRUITING